By Counterforce Health Team in Garadacimab (anti-FXIIa) — FDA-approved 2025 —

The Requirements Checklist to Get Garadacimab (Andembry) Covered by Humana in New York: Prior Authorization Forms, Appeals Process, and Approval Timeline

Answer Box: Getting Garadacimab Covered by Humana in New York

Garadacimab (Andembry) requires prior authorization from Humana in 2025-2026. Submit via Humana's provider portal with confirmed HAE diagnosis (ICD-10: D84.1), documented step therapy failures, and weight-based dosing justification. First step today: Verify your specific plan's formulary status using Humana's PA Search Tool. If denied, New York residents have strong appeal rights through the DFS External Appeal Program within 4 months of denial.

Table of Contents

  1. Who Should Use This Checklist
  2. Member & Plan Basics
  3. Clinical Criteria Requirements
  4. Coding and Billing Information
  5. Documentation Packet Essentials
  6. Submission Process
  7. Specialty Pharmacy Routing
  8. After Submission: What to Expect
  9. Common Denial Reasons & Prevention
  10. Appeals Process for New York Residents
  11. Quick Reference Checklist
  12. FAQ

Who Should Use This Checklist

This guide is designed for patients with hereditary angioedema (HAE) and their healthcare providers seeking Garadacimab (Andembry) coverage through Humana plans in New York. You'll need this if:

  • Your doctor has prescribed Garadacimab for HAE prophylaxis
  • You have Humana Medicare Advantage, Medicare Part D, or commercial insurance
  • You're facing a prior authorization requirement or denial
  • You need to understand New York's specific appeal rights

Expected outcome: Following this checklist increases your chances of first-time approval and provides a clear roadmap for appeals if needed.

Member & Plan Basics

Verify Active Coverage

  • Confirm your Humana plan type (Medicare Advantage, Part D, commercial)
  • Check that your coverage is active and premiums are current
  • Verify Garadacimab isn't excluded from your specific formulary

Prior Authorization Requirements

Garadacimab requires PA across Humana plans in 2025-2026 as a high-cost specialty biologic. Unlike Humana's elimination of certain outpatient service PAs, drug prior authorizations remain in effect.

Note: Private Fee-for-Service (PFFS) Medicare Advantage plans may only require notification rather than full PA.

Clinical Criteria Requirements

Confirmed HAE Diagnosis

Required lab evidence (ICD-10: D84.1):

  • Low serum C4 levels (CPT 86160)
  • Low C1-esterase inhibitor levels (CPT 86161)
  • Abnormal C1-INH functional testing

Step Therapy Documentation

Most Humana plans require documented trials and failures of:

  1. Lanadelumab (Takhzyro) - first-line prophylaxis
  2. Berotralstat (Orladeyo) - oral option
  3. C1-INH therapies (Haegarda, Cinryze) if applicable

Document specific reasons for discontinuation:

  • Inadequate response (breakthrough attacks)
  • Intolerable side effects
  • Contraindications or allergies
  • Access issues or injection site problems

FDA-Approved Indication

Garadacimab is approved for routine prophylaxis of HAE attacks in patients ≥12 years. Ensure your request aligns with this indication and includes appropriate weight-based dosing (200 mg subcutaneous every 2-4 weeks after initial 400 mg dose).

Coding and Billing Information

HCPCS/J-Codes

Garadacimab lacks a permanent J-code as of early 2026. Use unclassified codes:

  • J3490 (unclassified drugs) - most common
  • J3590 (unclassified biologics) - alternative
  • Include "Andembry (garadacimab-gxii) 200 mg/2 mL, CSL Behring" in Field 19

Administration Coding

  • CPT 96372 for subcutaneous therapeutic injection
  • Document self-administration capability if applicable
Tip: Check quarterly HCPCS updates for potential new product-specific codes.

Documentation Packet Essentials

Provider Note Requirements

Your healthcare provider's documentation must include:

Clinical History:

  • HAE attack frequency and severity before treatment
  • Impact on quality of life and daily activities
  • Emergency department visits or hospitalizations

Laboratory Evidence:

  • Complete HAE diagnostic panel results
  • C1-INH levels and functional testing
  • C4 complement levels

Treatment History:

  • Detailed record of prior HAE therapies
  • Specific dates, dosages, and duration of each trial
  • Documented reasons for discontinuation
  • Response to acute treatments

Medical Necessity Letter Components

A strong letter should address:

  1. Patient-specific clinical rationale for Garadacimab
  2. Contraindications or failures of preferred alternatives
  3. Expected outcomes and monitoring plan
  4. Dosing justification based on patient weight/response
  5. References to FDA labeling and HAE treatment guidelines

Submission Process

Electronic Submission (Preferred)

  1. Provider Portal: provider.humana.com
  2. Electronic Prior Authorization (ePA) - fastest processing
  3. Target response time: 1 business day for electronic requests (95% by January 2026)

Alternative Submission Methods

  • Fax: Use Humana Clinical Pharmacy Review forms
  • Phone: For urgent requests requiring expedited review
  • Mail: Less common, longer processing times

Required Fields That Cause Rejections

  • Complete member information (ID, DOB, contact details)
  • Prescriber NPI and DEA numbers
  • Specific drug name, strength, and NDC (include manufacturer)
  • ICD-10 diagnosis code (D84.1 for HAE)
  • Detailed clinical justification
  • Prior therapy documentation

Specialty Pharmacy Routing

CSL Behring's Preferred Network

Orsini Specialty Pharmacy handles Andembry distribution:

  • Enrollment: 800-356-4252
  • Fax: 847-631-6918
  • Home delivery available to New York addresses

Alternative Options

  • Accredo (via Evernorth) - supports HAE medications
  • CVS Caremark specialty network
  • OptionCare for complex therapies
Important: Coordinate with your specialty pharmacy before PA approval to ensure smooth transition after approval.

At Counterforce Health, we help patients and providers navigate complex prior authorization requirements by turning insurance denials into targeted, evidence-backed appeals. Our platform identifies denial reasons and crafts point-by-point rebuttals aligned with each plan's specific policies.

After Submission: What to Expect

Timeline Expectations

  • Electronic submissions: 1 business day (Humana's 2026 target)
  • Standard review: Up to 7 calendar days for Medicare Part D
  • Expedited review: 72 hours if health is jeopardized

Status Tracking

  1. Record confirmation numbers from all submissions
  2. Check status via provider portal or member services
  3. Document all communications with dates and representatives
  4. Set calendar reminders for follow-up if no response

What to Record

  • Submission date and method
  • Reference/confirmation numbers
  • Representative names and contact information
  • Any additional information requests
  • Decision date and details

Common Denial Reasons & Prevention

Denial Reason Prevention Strategy Required Documentation
Lack of confirmed HAE diagnosis Submit complete lab panel C1-INH levels, C4, functional testing
Insufficient step therapy Document specific failures Dates, doses, reasons for discontinuation
Incomplete clinical documentation Use comprehensive provider notes Attack frequency, severity, impact on life
Missing weight-based dosing justification Include patient weight and BSA Current weight, calculated dose rationale
REMS requirements not addressed Document provider training Certification of REMS compliance

Five Critical Pitfalls to Avoid

  1. Submitting without complete lab work - always include full HAE diagnostic panel
  2. Inadequate step therapy documentation - provide specific dates and failure reasons
  3. Generic clinical justification - personalize to patient's specific situation
  4. Missing provider credentials - ensure NPI and DEA numbers are current
  5. Incomplete contact information - verify all phone numbers and addresses

Appeals Process for New York Residents

Internal Appeal with Humana (First Step)

Deadline: 65 days from denial notice Submission options:

  • Online: resolutions.humana.com
  • Mail: Humana Grievances and Appeals, P.O. Box 14546, Lexington, KY 40512-4546
  • Expedited appeals: 72 hours for life-threatening situations (call 800-867-6601)

New York External Appeal (After Internal Denial)

New York's External Appeal Program provides independent review through the Department of Financial Services.

Key Details:

  • Deadline: 4 months from final internal denial (strictly enforced)
  • Cost: $25 for patients (waived for Medicaid/hardship), $50 for providers
  • Timeline: 30 days standard, 72 hours expedited (24 hours for urgent drug denials)
  • Outcome: Binding decision on Humana

Required Forms:

  1. New York State External Appeal Application
  2. Comprehensive Physician Attestation Form
  3. Medical Necessity - Expedited Form (if urgent)
New York Advantage: The state's external appeal program has overturned many specialty drug denials, especially when supported by strong clinical evidence and peer-reviewed literature.

Additional Resources:

  • Community Health Advocates: 888-614-5400 (free counseling on appeals)
  • DFS Consumer Assistance: Online portal for filing and tracking appeals

Quick Reference Checklist

Before You Start

  • Verify active Humana coverage
  • Confirm HAE diagnosis with complete lab panel
  • Document all prior therapy trials and failures
  • Gather provider notes and clinical documentation
  • Check current weight for dosing calculations

Submission Requirements

  • Complete PA form via provider portal
  • Include ICD-10 D84.1 (HAE diagnosis)
  • Attach medical necessity letter
  • Document step therapy failures
  • Include provider NPI and DEA numbers
  • Specify Andembry (garadacimab-gxii) with J3490/J3590

After Submission

  • Record confirmation numbers
  • Set follow-up reminders
  • Contact Orsini Specialty Pharmacy (800-356-4252)
  • Prepare appeal documentation if needed
  • Know your New York appeal rights and deadlines

FAQ

Q: How long does Humana prior authorization take for Garadacimab in New York? A: Electronic submissions target 1 business day by 2026; standard review allows up to 7 calendar days for Medicare Part D. Expedited reviews are completed within 72 hours if health is at risk.

Q: What if Garadacimab is non-formulary on my Humana plan? A: You can request a formulary exception with medical necessity documentation. New York residents also have external appeal rights if the internal exception is denied.

Q: Does step therapy apply if I failed treatments while living outside New York? A: Yes, document all prior therapy trials regardless of location. Include specific dates, dosages, and reasons for discontinuation from any state.

Q: Can I request an expedited appeal for Garadacimab? A: Yes, if delays would jeopardize your health. Contact Humana at 800-867-6601 for expedited internal appeals, or use New York's 72-hour external appeal process.

Q: What happens if I miss the 4-month deadline for New York external appeals? A: Missing this deadline forfeits your external appeal rights. Set calendar reminders immediately after receiving any denial to protect your appeal options.

Q: Are there patient assistance programs for Garadacimab? A: Contact CSL Behring's patient support program through Orsini Specialty Pharmacy (800-356-4252) for copay assistance and access programs.

When facing complex prior authorization challenges, Counterforce Health specializes in transforming insurance denials into successful appeals by identifying specific denial reasons and crafting evidence-based responses tailored to each payer's requirements.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms and medical circumstances. Always consult with your healthcare provider and insurance plan for specific guidance. Coverage policies and appeal procedures may change; verify current requirements with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.